By Deborah Erickson
Risk, like the poor, is always with us.
Cephalon Learns That Risk Returns
A risk-reduction strategy has brought Cephalon success, but now brings it face to face with a new set of risks that add up to a real management dilemma. The company is waiting to hear whether FDA will approve an expanded label for Provigil, a treatment for narcolepsy. A yes could position the product for marketing to GPs. The trouble is that four big generic companies are taking aim at Provigil. Should Cephalon spend on a big sales force, or seek a co-promotion deal that, given the situation, is bound to have tough terms? This much is clear: no one escapes risk.
More from Leadership
• By
Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.
• By
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
More from In Vivo
• By
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
• By
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.